These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29221430)

  • 1. The study of intravitreal drug pharmacokinetics: does it matter? and if so, how?
    Stewart MW
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):5-7. PubMed ID: 29221430
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development.
    del Amo EM; Vellonen KS; Kidron H; Urtti A
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):215-26. PubMed ID: 25603198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
    Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of Drug Pharmacokinetics at the Site of Action.
    Rizk ML; Zou L; Savic RM; Dooley KE
    Clin Transl Sci; 2017 May; 10(3):133-142. PubMed ID: 28160433
    [No Abstract]   [Full Text] [Related]  

  • 5. Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections.
    Meyer CH; Krohne TU; Charbel Issa P; Liu Z; Holz FG
    Dev Ophthalmol; 2016; 55():63-70. PubMed ID: 26501462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primer on clinical pharmacokinetics.
    Bauer LA
    Am J Hosp Pharm; 1983 Oct; 40(10):1637-41. PubMed ID: 6638025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema.
    Zhang Y; Yao Z; Kaila N; Kuebler P; Visich J; Maia M; Tuomi L; Ehrlich JS; Rubio RG; Campochiaro PA
    Ophthalmology; 2014 Nov; 121(11):2237-46. PubMed ID: 25001159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ICH discussion on pharmacokinetics and toxicokinetics and contributors.
    Ohno Y
    Drug Metab Pharmacokinet; 2013; 28(5):379-82. PubMed ID: 24162438
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent developments in ocular drug delivery.
    Chen H
    J Drug Target; 2015; 23(7-8):597-604. PubMed ID: 26453157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADMET-SMi's fourth annual meeting. 1-2 July 2009, London, UK.
    Gater D
    IDrugs; 2009 Sep; 12(9):547-9. PubMed ID: 19697271
    [No Abstract]   [Full Text] [Related]  

  • 11. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
    Erie JC; Barkmeier AJ; Hodge DO; Mahr MA
    Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.
    Mordenti J; Cuthbertson RA; Ferrara N; Thomsen K; Berleau L; Licko V; Allen PC; Valverde CR; Meng YG; Fei DT; Fourre KM; Ryan AM
    Toxicol Pathol; 1999; 27(5):536-44. PubMed ID: 10528633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF.
    Stewart MW
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):167-80. PubMed ID: 24483136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors.
    Krohne TU; Muether PS; Stratmann NK; Holz FG; Kirchhof B; Meyer CH; Fauser S
    Retina; 2015 Jan; 35(1):69-74. PubMed ID: 25077535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of intravitreal ranibizumab (Lucentis).
    Bakri SJ; Snyder MR; Reid JM; Pulido JS; Ezzat MK; Singh RJ
    Ophthalmology; 2007 Dec; 114(12):2179-82. PubMed ID: 18054637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes.
    Edington M; Connolly J; Chong NV
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1217-1224. PubMed ID: 29134820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant.
    Park J; Bungay PM; Lutz RJ; Augsburger JJ; Millard RW; Sinha Roy A; Banerjee RK
    J Control Release; 2005 Jul; 105(3):279-95. PubMed ID: 15896868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing drug development and use in patients with kidney disease.
    Nolin TD; Arya V; Sitar DS; Pfister M
    J Clin Pharmacol; 2011 May; 51(5):628-30. PubMed ID: 21525394
    [No Abstract]   [Full Text] [Related]  

  • 20. Arteriosclerotic Changes after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Drugs in Patients with Exudative Age-Related Macular Degeneration.
    Shiba T; Takahashi M; Yoshida I; Taniguchi H; Matsumoto T; Hori Y
    Ophthalmologica; 2016; 235(4):225-32. PubMed ID: 27082736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.